Takeda Pharmaceutical Company Limited (TYO:4502)
6,869.00
-62.00 (-0.89%)
Nov 18, 2026, 3:30 PM JST
TYO:4502 Revenue
Takeda Pharmaceutical Company had revenue of 1.19T JPY in the quarter ending September 30, 2026, with 6.68% growth. This brings the company's total for the last twelve months to 4.69T, up 6.25% year-over-year. In the fiscal year ending March 31, 2026, Takeda Pharmaceutical Company had annual revenue of 4.51T, down -1.66%. That makes Takeda Pharmaceutical Company the 476th largest company in the world by revenue and 45th in Japan.
Revenue (ttm)
4.69T
Revenue Growth
+6.25%
P/S Ratio
2.34
Revenue / Employee
99.79M
Employees
47,029
Market Cap
10.97T
Revenue by Segment
Fiscal year ended Mar 31, 2026 See the full TYO:4502 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 4.51T | -75.83B | -1.66% |
| Mar 31, 2025 | 4.58T | 317.79B | 7.45% |
| Mar 31, 2024 | 4.26T | 236.26B | 5.87% |
| Mar 31, 2023 | 4.03T | 458.50B | 12.85% |
| Mar 31, 2022 | 3.57T | 371.19B | 11.61% |
| Mar 31, 2021 | 3.20T | -93.38B | -2.84% |
| Mar 31, 2020 | 3.29T | 1.19T | 56.93% |
| Mar 31, 2019 | 2.10T | 326.69B | 18.45% |
| Mar 31, 2018 | 1.77T | 38.48B | 2.22% |
| Mar 31, 2017 | 1.73T | -75.33B | -4.17% |
| Mar 31, 2016 | 1.81T | 29.55B | 1.66% |
| Mar 31, 2015 | 1.78T | 86.14B | 5.09% |
| Mar 31, 2014 | 1.69T | 134.42B | 8.63% |
| Mar 31, 2013 | 1.56T | 48.34B | 3.20% |
| Mar 31, 2012 | 1.51T | 89.55B | 6.31% |
| Mar 31, 2011 | 1.42T | -46.58B | -3.18% |
| Mar 31, 2010 | 1.47T | -72.37B | -4.70% |
| Mar 31, 2009 | 1.54T | 163.53B | 11.90% |
| Mar 31, 2008 | 1.37T | 69.64B | 5.34% |
| Mar 31, 2007 | 1.31T | 92.96B | 7.67% |
| Mar 31, 2006 | 1.21T | 89.25B | 7.95% |
| Mar 31, 2005 | 1.12T | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Eisai | 895.33B |
| Shionogi & | 637.09B |
| Sumitomo Pharma | 492.66B |
| Towa Pharmaceutical | 285.49B |
| Tsumura & Co. | 206.16B |
| Sawai Group Holdings | 203.79B |
| Nippon Shinyaku | 180.29B |
| Mochida Pharmaceutical | 126.33B |
Takeda Pharmaceutical Company News
- 1 day ago - Takeda Pharmaceutical Company Transcript: Jefferies Global Healthcare Conference - Transcripts
- 2 days ago - Takeda price target raised to $26.70 from $21.90 at BofA - TheFly
- 6 days ago - Alkermes position intact after Takeda drug pricing, says Needham - TheFly
- 6 days ago - Takeda Pharmaceutical's ORZEYFUL Is Now Available In US For Narcolepsy Type 1 Treatment - Nasdaq
- 6 days ago - Takeda announces Orzeyful CIV is now available in U.S. - TheFly
- 6 days ago - Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdle - Reuters
- 6 days ago - Takeda Launches ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1 Now Available in the United States - Business Wire
- 19 days ago - Friday's ETF Movers: PPH, PSI - Nasdaq